IDEXX Laboratories Says It Expanded Fecal Dx Antigen Testing Platform With Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories announced the expansion of its Fecal Dx antigen testing platform to include Cystoisospora detection. This marks the second expansion of the platform in less than two years, aiming to detect common intestinal parasites earlier and uncover more infections.

January 12, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEXX Laboratories has expanded its Fecal Dx antigen testing platform to include detection of Cystoisospora, which is expected to improve early detection of intestinal parasites in animals.
The expansion of IDEXX's Fecal Dx antigen testing platform is directly related to the company's core business of veterinary diagnostics. By adding Cystoisospora detection, IDEXX enhances its product offering, which could lead to increased usage and sales. This innovation is likely to be viewed positively by investors and could have a favorable impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100